Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.
Journal
Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063
Informations de publication
Date de publication:
12 Jul 2023
12 Jul 2023
Historique:
pubmed:
25
5
2023
medline:
25
5
2023
entrez:
24
5
2023
Statut:
aheadofprint
Résumé
To date, there are no data on switching to dual pathway inhibition (DPI) patients who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen. To assess the feasibility of switching from DAPT to DPI and to compare the pharmacodynamic (PD) profiles of these treatments. This was a prospective, randomized, PD study conducted in 90 patients with chronic coronary syndrome (CCS) on DAPT with aspirin (81 mg/qd) plus a P2Y Switching from DAPT to DPI occurred without major side effects. DAPT was associated with enhanced P2Y In patients with CCS, switching from different DAPT regimens to DPI was feasible, showing enhanced P2Y http://www. gov Unique Identifier: NCT04006288.
Sections du résumé
BACKGROUND
BACKGROUND
To date, there are no data on switching to dual pathway inhibition (DPI) patients who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen.
OBJECTIVES
OBJECTIVE
To assess the feasibility of switching from DAPT to DPI and to compare the pharmacodynamic (PD) profiles of these treatments.
METHODS
METHODS
This was a prospective, randomized, PD study conducted in 90 patients with chronic coronary syndrome (CCS) on DAPT with aspirin (81 mg/qd) plus a P2Y
RESULTS
RESULTS
Switching from DAPT to DPI occurred without major side effects. DAPT was associated with enhanced P2Y
CONCLUSION
CONCLUSIONS
In patients with CCS, switching from different DAPT regimens to DPI was feasible, showing enhanced P2Y
CLINICAL TRIAL REGISTRATION
BACKGROUND
http://www.
CLINICALTRIALS
RESULTS
gov Unique Identifier: NCT04006288.
Banques de données
ClinicalTrials.gov
['NCT04006288']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
Dr. Franchi declares that he has received payment as an individual for consulting fee or honoraria from AstraZeneca, Bayer, and Sanofi; and institutional payments for grants from PLx Pharma and The Scott R. MacKenzie Foundation. Dr. Angiolillo declares that he has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi and Vectura; Dr. Angiolillo also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, and the Scott R. MacKenzie Foundation. Other authors have nothing to declare.